Page 1162 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 82 Immune Reconstitution Therapy for Immunodeficiency 1127

of mAbs against CD117 (c-kit) has been proposed to displace 5. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe
autologous stem cells and favor engraftment of donor-derived combined immunodeficiency in 11 screening programs in the United
cells, while avoiding the drug-related toxicity of chemotherapy States. JAMA 2014;312:729–38.
48
and radiotherapy. Recognition that B-cell engraftment after 6. Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation
for severe combined immunodeficiency. JAMA 2006;295:508–18.
HSCT is hampered by competition between host and donor 7. Gennery AR, Cant AJ. Cord blood stem cell transplantation in primary
49
early B-cell precursors may prompt novel forms of conditioning immune deficiencies. Curr Opin Allergy Clin Immunol 2007;7:528–34.
regimens targeted to host pro-B lymphocytes, in an attempt to 8. Hassan A, Lee P, Maggina P, et al. Host natural killer immunity is a key
facilitate development of donor-derived B cells, even in the indicator of permissiveness for donor cell engraftment in patients with
unconditioned HLA-identical setting. severe combined immunodeficiency. J Allergy Clin Immunol
Strategies aimed at improving thymic function after HSCT 2014;133:1660–6.
may include (i) protection of thymic stroma that supports 9. Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning
thymopoiesis and (ii) direct stimulation of early T-cell progenitors. regimens for hematopoietic stem cell transplantation in children with
Keratinocyte growth factor (KGF) is potentially attractive because primary immunodeficiency: United Kingdom experience. Blood
it protects the thymic stroma. Administration of KGF before 2011;117:4367–75.
HSCT has been shown to enhance thymopoiesis and peripheral 10. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet
2009;373:1550–61.
T-cell numbers and to reduce the incidence and severity of GvHD 11. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical
50
in murine models of HSCT. However, more must be learned practice in chronic graft-versus-host disease (GVHD): first-line and
about the long-term outcome of this treatment before clinical topical treatment of chronic GVHD. Biol Blood Marrow Transplant
trials can be started. 2010;16:1611–28.
Attempts to accelerate immune reconstitution might be based 12. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on
on the use of cytokines, such as IL-7, which promote T-cell clinical practice in chronic GVHD: second-line treatment of chronic
development and maturation in the thymus. However, experience graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1–17.
in severely immunodeficient mice has shown that infusion of 13. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing
IL-7 provides limited benefit in the MHC-compatible or partially infectious complications among hematopoietic cell transplantation
compatible setting, whereas it has facilitated T-cell development recipients: a global perspective. Biol Blood Marrow Transplant
2009;15:1143–238. Erratum in: Biol Blood Marrow Transplant
in a fully mismatched setting. 2010;16:294.
14
Finally, besides use of virus-specific CTLs, infusion of donor 14. Naik S, Nicholas SK, Martinez CA, et al. Adoptive immunotherapy for
T cells that have antiinfective activity but no GvHD activity primary immunodeficiency disorders with virus-specific T lymphocytes. J
might help reduce infection-related mortality after HSCT. Such Allergy Clin Immunol 2016;137:1498–505.
strategy could be based on removal of alloreactive cells by negative 15. Teigland CL, Parrott RE, Buckley RH. Long-term outcome of
selection using anti-CD25 or anti-CD69 antibodies. non-ablative BMT in patients with SCID. Bone Marrow Transplant
2013;48:1050–5.
ON tHE HOrIZON 16. Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs
RAG deficiencies following HCT: increased risk of late toxicity in
The following strategies may help improve even further the outcome of ARTEMIS-deficient SCID. Blood 2014;123:281–9.
hematopoietic stem cell transplantation (HSCT) for primary immunode- 17. Hassan A, Lee P, Maggina P, et al. Host natural killer immunity is a key
ficiency (PID) in the future: indicator of permissiveness for donor cell engraftment in patients with
Methods to improve and sustain engraftment of stem cells severe combined immunodeficiency. J Allergy Clin Immunol
Strategies to facilitate engraftment and reduce the occurrence of graft- 2014;133:1660–6.
versus-host disease (GvHD) in patients with mismatched or matched 18. Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem
unrelated donor (MUD) transplant cell transplantation for adenosine deaminase-deficient severe combined
Approaches to increase thymopoiesis and accelerate immune immunodeficiency. Blood 2012;120:3615–24.
reconstitution 18a. Buckley RH. Transplantation of hematopoietic stem cells in human
Design of therapeutic strategies to reduce the infectious complications severe combined immunodeficiency: longterm outcomes. Immunol Res
of HSCT 2011;49(1-3):25–43.
19. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after
hematopoietic stem cell transplantation of a single-center cohort of 90
Please check your eBook at https://expertconsult.inkling.com/ patients with severe combined immunodeficiency. Blood
for self-assessment questions. See inside cover for registration 2009;113:4114–24.
details. 20. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe
combined immunodeficiency in 11 screening programs in the United
REFERENCES States. JAMA 2014;312:729–38.
21. Sarzotti-Kelsoe M, Win CM, Parrott RE, et al. Thymic output, T-cell
1. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of diversity, and T-cell function in long-term human SCID chimeras. Blood
hematopoietic stem cells and long-term survival for primary 2009;114:1445–53.
immunodeficiencies in Europe: entering a new century, do we do better? J 22. Mazzolari E, Forino C, Guerci S, et al. Long-term immune reconstitution
Allergy Clin Immunol 2010;126:602–10.e1–11. and clinical outcome after stem cell transplantation for severe T-cell
2. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe immunodeficiency. J Allergy Clin Immunol 2007;120:892–9.
combined immunodeficiency, 2000-2009. N Engl J Med 2014;371:434–46. 23. Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic
3. Klein OR, Chen AR, Gamper C, et al. Alternative-donor hematopoietic criteria for severe combined immunodeficiency disease (SCID), leaky
stem cell transplantation with post-transplantation cyclophosphamide SCID, and Omenn syndrome: the Primary Immune Deficiency
for nonmalignant disorders. Biol Blood Marrow Transplant Treatment Consortium experience. J Allergy Clin Immunol 2014;133:
2016;22:895–901. 1092–8.
+
+
4. Handgretinger R. Negative depletion of CD3 and TcRαββ T cells. Curr 24. Markert ML, Devlin BH, Chinn IK, et al. Thymus transplantation in
Opin Hematol 2012;19:434–9. complete DiGeorge anomaly. Immunol Res 2009;44:61–70.